Neoadjuvant treatment for esophageal squamous cell carcinoma

Table 2 Neoadjuvant chemotherapy treatment and outcomes for esophageal squamous cell carcinoma

Ref.	Year of publication	Histology	Treatment	n	Median survival (mo)	5-yr overall survival (%)	P
Schlag[26]	1992	SCC	FU, CDDP → Surgery	22	10		NS
			Surgery	24	10
Nygaard et al[20]	1992	SCC	CDDP, BL → Surgery	44	7	31
			Surgery	41	7	9
Maipang et al[27]	1994	SCC	CDDP, BL, VI → Surgery	24	17	311	NS
			Surgery	22	17	36
Law et al[28]	1997	SCC	FU, CDDP → Surgery	66	17	401	NS
			Surgery	69	13	13
Ancona et al[29]	2001	SCC	FU, CDDP → Surgery	47	25	34	NS
			Surgery	47	24	22
Kelsen et al[32]	2007	AC/SCC	FU, CDDP → Surgery	213	15	19	NS
(RTOG 8911)		(47%)	Surgery	227	16	20
Allum et al[31]	2009	AC/SCC	FU, CDDP → Surgery	400	17	23	< 0.01
(OEO2)		(31%)	Surgery	402	13	17
Ando et al[7]	2012	SCC	FU, CDDP → Surgery	164		55	0.01
(JCOG9907)			Surgery → FU, CDDP	166		43

¹3-yr overall survival. AC: Adenocarcinoma; BL: Bleomycin; CDDP: Cisplatin; FU: Fluorouracil; NS: Not significant; SCC: Squamous cell carcinoma; VI: Vinblastine; JCOG: Japan Clinical Oncology Group study.